- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 13 January 2020, the European Commission withdrew the marketing authorisation for Clopidogrel ratiopharm GmbH (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Archie Samuel s.r.o., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.
Clopidogrel ratiopharm GmbH was granted marketing authorisation in the EU on 28 July 2009 for prevention of atherothrombotic events. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.
Clopidogrel ratiopharm GmbH is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU.
The European Public Assessment Report (EPAR) for Clopidogrel ratiopharm GmbH is updated to indicate that the marketing authorisation is no longer valid.
Product information
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Clopidogrel ratiopharm GmbH
- Active substance
- clopidogrel
- International non-proprietary name (INN) or common name
- clopidogrel
- Therapeutic area (MeSH)
- Peripheral Vascular Diseases
- Acute Coronary Syndrome
- Myocardial Infarction
- Stroke
- Anatomical therapeutic chemical (ATC) code
- B01AC04
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;
- patients suffering from acute coronary syndrome:
- non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q wave-myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
- ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.